Gilbert Kliman Sells 5,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) Director Gilbert Kliman sold 5,000 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total value of $536,350.00. Following the completion of the transaction, the director owned 34,905 shares of the company’s stock, valued at $3,744,259.35. The trade was a 12.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Glaukos Price Performance

Shares of NYSE GKOS opened at $109.00 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71. The firm has a market capitalization of $6.26 billion, a P/E ratio of -70.78 and a beta of 0.69. The company’s fifty day moving average is $91.77 and its two-hundred day moving average is $92.79.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business’s revenue was up 38.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.28) EPS. Analysts forecast that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GKOS. BTIG Research boosted their price target on Glaukos from $104.00 to $116.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Truist Financial set a $120.00 target price on Glaukos in a research report on Thursday, October 30th. The Goldman Sachs Group assumed coverage on Glaukos in a report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 target price on the stock. UBS Group reaffirmed a “buy” rating and set a $140.00 price target on shares of Glaukos in a research note on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $120.62.

Institutional Trading of Glaukos

Institutional investors and hedge funds have recently made changes to their positions in the stock. LPL Financial LLC increased its position in Glaukos by 25.1% during the 1st quarter. LPL Financial LLC now owns 15,775 shares of the medical instruments supplier’s stock worth $1,553,000 after purchasing an additional 3,163 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Glaukos during the first quarter worth about $31,474,000. HighTower Advisors LLC raised its position in shares of Glaukos by 12.9% in the first quarter. HighTower Advisors LLC now owns 3,722 shares of the medical instruments supplier’s stock valued at $366,000 after buying an additional 424 shares during the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in shares of Glaukos during the first quarter valued at approximately $207,000. Finally, Russell Investments Group Ltd. boosted its position in Glaukos by 174.9% during the first quarter. Russell Investments Group Ltd. now owns 38,393 shares of the medical instruments supplier’s stock worth $3,779,000 after acquiring an additional 24,428 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.